CG Oncology (CGON) Competitors

$66.93 -2.61 (-3.75%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$66.03 -0.90 (-1.34%)

As of 05/15/2026 07:40 PM Eastern

CGON vs. ROIV, MRNA, VTRS, GMAB, and ASND

Should you buy CG Oncology stock or one of its competitors? MarketBeat compares CG Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CG Oncology include Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does CG Oncology compare to Roivant Sciences?

CG Oncology (NASDAQ:CGON) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

CG Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 22.11%. Roivant Sciences has a consensus price target of $30.55, indicating a potential upside of 4.30%. Given CG Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

CG Oncology has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, CG Oncology had 27 more articles in the media than Roivant Sciences. MarketBeat recorded 33 mentions for CG Oncology and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.56 beat CG Oncology's score of 0.24 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has higher earnings, but lower revenue than Roivant Sciences. CG Oncology is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A
Roivant Sciences	$29.05M	721.61	-$171.98M	-$1.17	N/A

Summary

Roivant Sciences beats CG Oncology on 8 of the 15 factors compared between the two stocks.

How does CG Oncology compare to Moderna?

Moderna (NASDAQ:MRNA) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

CG Oncology has lower revenue, but higher earnings than Moderna. CG Oncology is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to Moderna's net margin of -143.55%. CG Oncology's return on equity of -23.33% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 9 more articles in the media than Moderna. MarketBeat recorded 33 mentions for CG Oncology and 24 mentions for Moderna. Moderna's average media sentiment score of 0.74 beat CG Oncology's score of 0.24 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	14 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Moderna presently has a consensus price target of $35.73, indicating a potential downside of 27.13%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 22.11%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

75.3% of Moderna shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

CG Oncology beats Moderna on 9 of the 15 factors compared between the two stocks.

How does CG Oncology compare to Viatris?

Viatris (NASDAQ:VTRS) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

CG Oncology has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 24 more articles in the media than Viatris. MarketBeat recorded 33 mentions for CG Oncology and 9 mentions for Viatris. Viatris' average media sentiment score of 0.73 beat CG Oncology's score of 0.24 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Viatris currently has a consensus price target of $15.71, suggesting a potential downside of 4.65%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 22.11%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

79.9% of Viatris shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viatris has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Summary

CG Oncology beats Viatris on 8 of the 15 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.45	$963M	$1.32	20.11
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 26 more articles in the media than Genmab A/S. MarketBeat recorded 33 mentions for CG Oncology and 7 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.60 beat CG Oncology's score of 0.24 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Genmab A/S presently has a consensus price target of $39.07, suggesting a potential upside of 47.22%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 22.11%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Genmab A/S is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Summary

Genmab A/S beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

26.6% of CG Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. CG Oncology is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.42	-$258M	$8.67	27.74
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

Ascendis Pharma A/S has a net margin of 57.87% compared to CG Oncology's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 26 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 33 mentions for CG Oncology and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.47 beat CG Oncology's score of 0.24 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ascendis Pharma A/S presently has a consensus price target of $291.78, suggesting a potential upside of 21.32%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 22.11%. Given CG Oncology's higher possible upside, analysts plainly believe CG Oncology is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats CG Oncology on 10 of the 15 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.90B	$3.38B	$6.42B	$12.48B
Dividend Yield	N/A	2.32%	2.80%	5.25%
P/E Ratio	N/A	18.50	20.40	25.24
Price / Sales	1,461.19	294.63	566.15	82.24
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	5.41	6.63	9.87	6.90
Net Income	-$160.99M	$24.40M	$3.57B	$334.66M
7 Day Performance	-3.86%	4.15%	0.31%	0.13%
1 Month Performance	0.89%	-2.65%	-1.27%	1.11%
1 Year Performance	163.19%	62.87%	33.54%	30.62%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.4829 of 5 stars	$66.93 -3.8%	$81.73 +22.1%	+164.0%	$5.90B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
ROIV Roivant Sciences	2.164 of 5 stars	$28.32 -0.1%	$30.55 +7.9%	+172.2%	$20.27B	$29.05M	N/A	860
MRNA Moderna	1.5943 of 5 stars	$46.71 -1.2%	$35.73 -23.5%	+107.4%	$18.45B	$2.20B	N/A	4,700	Gap Down
VTRS Viatris	2.7335 of 5 stars	$15.53 +2.2%	$14.67 -5.6%	+87.5%	$18.08B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.2577 of 5 stars	$27.53 +1.8%	$39.07 +41.9%	+35.1%	$17.16B	$3.72B	17.76	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does CG Oncology compare to Roivant Sciences?

Summary

How does CG Oncology compare to Moderna?

Summary

How does CG Oncology compare to Viatris?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. ROIV, MRNA, VTRS, GMAB, and ASND

How does CG Oncology compare to Roivant Sciences?

Which has more risk and volatility, CGON or ROIV?

Do analysts prefer CGON or ROIV?

Is CGON or ROIV more profitable?

Do insiders & institutionals believe in CGON or ROIV?

Does the media favor CGON or ROIV?

Which has higher earnings & valuation, CGON or ROIV?

Summary

How does CG Oncology compare to Moderna?

Which has preferable valuation & earnings, MRNA or CGON?

Is MRNA or CGON more profitable?

Does the media prefer MRNA or CGON?

Do analysts prefer MRNA or CGON?

Do institutionals & insiders believe in MRNA or CGON?

Which has more volatility & risk, MRNA or CGON?

Summary

How does CG Oncology compare to Viatris?

Which has higher valuation and earnings, VTRS or CGON?

Is VTRS or CGON more profitable?

Does the media refer more to VTRS or CGON?

Do analysts recommend VTRS or CGON?

Do insiders & institutionals hold more shares of VTRS or CGON?

Which has more volatility and risk, VTRS or CGON?

Summary

How does CG Oncology compare to Genmab A/S?

Do institutionals & insiders hold more shares of GMAB or CGON?

Which has stronger valuation & earnings, GMAB or CGON?

Is GMAB or CGON more profitable?

Does the media refer more to GMAB or CGON?

Do analysts recommend GMAB or CGON?

Which has more risk and volatility, GMAB or CGON?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Do institutionals & insiders hold more shares of ASND or CGON?

Which has stronger valuation & earnings, ASND or CGON?

Is ASND or CGON more profitable?

Does the media refer more to ASND or CGON?

Do analysts recommend ASND or CGON?

Which has more risk and volatility, ASND or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools